Vilya

About Vilya

Vilya develops a computational biotechnology platform that designs novel molecular structures to target disease biology, utilizing advanced algorithms to explore uncharted chemical space. This approach enables the creation of medicines with enhanced drug-like properties, addressing previously inaccessible therapeutic targets across various medical indications.

```xml <problem> Many therapeutic targets are considered undruggable due to limitations in traditional drug discovery methods, which struggle to identify molecules with the necessary properties to effectively bind and modulate these targets. Conventional high-throughput screening is often inefficient and costly, failing to explore the vast chemical space needed to discover novel drug candidates. </problem> <solution> Vilya is developing a computational biotechnology platform that designs novel molecular structures to target previously inaccessible disease biology. The platform utilizes advanced algorithms to explore uncharted chemical space, enabling the creation of medicines with enhanced drug-like properties. By leveraging computational approaches, Vilya aims to overcome the limitations of traditional drug discovery and create a new class of medicines that can precisely target disease biology. The platform is designed to make high throughput screening obsolete by computationally designing molecules. </solution> <features> - Computational design of novel molecular structures not found in nature - Advanced algorithms to explore uncharted chemical space - Enhanced drug-like properties for improved target binding and modulation - Ability to target previously inaccessible therapeutic targets - Macrocycle design capabilities </features> <target_audience> Vilya's primary target audience includes pharmaceutical companies and research institutions seeking novel drug candidates for challenging therapeutic targets across various medical indications. </target_audience> ```

What does Vilya do?

Vilya develops a computational biotechnology platform that designs novel molecular structures to target disease biology, utilizing advanced algorithms to explore uncharted chemical space. This approach enables the creation of medicines with enhanced drug-like properties, addressing previously inaccessible therapeutic targets across various medical indications.

Where is Vilya located?

Vilya is based in South San Francisco, United States.

When was Vilya founded?

Vilya was founded in 2022.

Who founded Vilya?

Vilya was founded by David Baker and Cyrus Harmon.

  • David Baker - Founder
  • Cyrus Harmon - CEO
Location
South San Francisco, United States
Founded
2022
Employees
46 employees
Looking for specific startups?
Try our free semantic startup search

Vilya

Score: 100/100
AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

Vilya develops a computational biotechnology platform that designs novel molecular structures to target disease biology, utilizing advanced algorithms to explore uncharted chemical space. This approach enables the creation of medicines with enhanced drug-like properties, addressing previously inaccessible therapeutic targets across various medical indications.

vilyatx.com2K+
Founded 2022South San Francisco, United States

Funding

No funding information available. Click "Fetch funding" to run a targeted funding scan.

Team (40+)

David Baker

Founder

Cyrus Harmon

CEO

Patrick Salveson

CTO

Adam Moyer

Director of Molecular Design

Nao Hiranuma

Director of Machine Learning Research

Company Description

Problem

Many therapeutic targets are considered undruggable due to limitations in traditional drug discovery methods, which struggle to identify molecules with the necessary properties to effectively bind and modulate these targets. Conventional high-throughput screening is often inefficient and costly, failing to explore the vast chemical space needed to discover novel drug candidates.

Solution

Vilya is developing a computational biotechnology platform that designs novel molecular structures to target previously inaccessible disease biology. The platform utilizes advanced algorithms to explore uncharted chemical space, enabling the creation of medicines with enhanced drug-like properties. By leveraging computational approaches, Vilya aims to overcome the limitations of traditional drug discovery and create a new class of medicines that can precisely target disease biology. The platform is designed to make high throughput screening obsolete by computationally designing molecules.

Features

Computational design of novel molecular structures not found in nature

Advanced algorithms to explore uncharted chemical space

Enhanced drug-like properties for improved target binding and modulation

Ability to target previously inaccessible therapeutic targets

Macrocycle design capabilities

Target Audience

Vilya's primary target audience includes pharmaceutical companies and research institutions seeking novel drug candidates for challenging therapeutic targets across various medical indications.